pandem
coronaviru
diseas
caus
sever
acut
respiratori
syndrom
coronaviru
continu
spread
world
signific
impact
global
public
health
economi
accord
situat
report
publish
world
health
organ
total
confirm
case
death
identifi
global
march
howev
antivir
medic
vaccin
proven
efficaci
treat
prevent
human
coronaviru
infect
henc
crucial
urgent
need
identifi
effect
safe
avail
treatment
strategi
diseas
novel
human
coronaviru
identifi
envelop
positivesens
singlestrand
rna
betacoronaviru
structur
similar
middl
east
respiratori
syndrom
coronaviru
merscov
identifi
sar
mer
outbreak
consid
threat
epidem
past
experi
treatment
sar
mer
mani
effort
vaccin
treatment
strategi
develop
made
vigor
review
focus
potenti
therapeut
agent
report
experi
treat
infect
lopinavirritonavir
lpvrtv
antiretrovir
proteas
inhibitor
use
combin
treatment
human
immunodefici
viru
hiv
infect
sinc
rtv
use
togeth
lpv
increas
lpv
halflif
via
inhibit
cytochrom
act
pharmacokinet
lpv
act
viral
proteas
report
promis
result
lotu
china
trial
lopinavir
trial
suppress
china
random
control
openlabel
studi
initi
investig
efficaci
safeti
oral
lpvrtv
infect
adult
patient
hospit
sever
patient
random
ratio
receiv
either
lpvrtv
mg
twice
day
addit
standard
care
n
standard
care
alon
n
day
result
show
differ
clinic
improv
two
group
hazard
ratio
ci
mortal
day
also
similar
group
vs
ci
author
conclud
benefit
observ
lpvrtv
treatment
beyond
standard
care
adult
patient
hospit
sever
remdesivir
rdv
novel
antivir
drug
develop
gilead
scienc
origin
treatment
ebola
viru
diseas
marburg
viru
infect
rdv
adenosin
nucleotid
analogu
broadspectrum
antivir
activ
act
inhibitor
rnadepend
rna
polymeras
rdrp
rdv
inhibit
viral
replic
prematur
termin
rna
transcript
demonstr
improv
pulmonari
function
reduc
lung
viral
load
mice
infect
recent
vitro
studi
indic
rdv
potent
inhibit
vero
singl
case
report
holshu
et
describ
clinic
improv
rdv
use
treat
first
us
case
sever
random
control
trial
current
conduct
evalu
efficaci
safeti
rdv
patient
two
phase
iii
trial
initi
china
februari
aim
evalu
rdv
hospit
adult
patient
mildmoder
sever
rdv
mg
day
mg
daili
day
vs
placebo
preliminari
result
trial
expect
announc
end
april
thereaft
three
intern
phase
iii
trial
launch
usa
asia
includ
hospit
adult
patient
rdv
mg
day
mg
daili
day
cours
vs
placebo
patient
moder
rdv
mg
day
mg
daili
day
vs
rdv
mg
day
mg
daili
day
patient
sever
rdv
mg
day
mg
daili
day
vs
rdv
mg
day
mg
daili
day
two
trial
estim
complet
may
favipiravir
fpv
guanin
analogu
select
inhibit
rdrp
rna
virus
approv
treatment
novel
influenza
sinc
vitro
studi
show
inhibit
favipiravir
vero
cell
cai
et
al
conduct
open
label
control
studi
examin
effect
fpv
mg
twice
daili
day
mg
twice
daili
day
versu
lpvrtv
mg
twice
daili
addit
mg
twice
daili
inhal
treatment
preliminari
result
report
signific
clinic
differ
fpv
patient
lpvrtv
patient
median
viral
clearanc
time
vs
day
p
chest
imag
improv
rate
vs
p
chloroquin
cq
hydroxychloroquin
aminoquinolin
use
treat
malaria
autoimmun
diseas
year
two
drug
weak
diprot
base
elev
ph
endosom
prevent
viral
fusion
recent
vitro
studi
report
cq
hcq
multipl
infect
moi
vero
cell
sever
clinic
trial
conduct
china
evalu
efficaci
safeti
cq
hcq
one
reveal
chloroquin
superior
control
group
clinic
improv
promot
virusneg
convers
shorten
diseas
meanwhil
preliminari
studi
franc
evalu
efficaci
hcq
patient
two
group
studi
patient
receiv
hcq
mg
tid
day
patient
receiv
standard
care
six
hcq
group
patient
lost
follow
due
earli
cessat
treatment
six
patient
hcq
group
receiv
addit
azithromycin
mg
day
mg
daili
day
prevent
bacteri
superinfect
result
show
virolog
cure
rate
significantli
higher
hcq
combin
azithromycintr
patient
compar
hcq
group
control
group
vs
vs
p
although
studi
demonstr
promis
result
larger
trial
still
need
verifi
efficaci
safeti
hcq
alon
combin
azithromycin
addit
hcq
postexposur
prophylaxispreempt
therapi
infect
evalu
usa
use
regimen
mg
oral
follow
hour
mg
mg
day
four
consecut
day
result
shall
report
soon
interferon
broadspectrum
antivir
agent
interact
tolllik
receptor
inhibit
viral
interferonalfa
beta
demonstr
activ
interferonbeta
display
potent
activ
reduc
merscov
replic
iuml
ribavirin
guanosin
analogu
broadspectrum
antivir
agent
use
combin
interferon
treatment
chronic
hepat
c
ribavirin
combin
lpvrtv
use
treat
infect
lower
risk
acut
respiratori
distress
syndrom
ard
death
lpvrtv
howev
recent
vitro
studi
result
reveal
ribavirin
requir
high
effect
concentr
ongo
trial
evalu
efficaci
safeti
interferonalpha
use
combin
ribavirin
lpvrtv
ribavirin
plu
lpvrtv
infect
china
current
conduct
interleukin
il
report
releas
consider
sar
mer
patient
might
play
role
pathogenesi
recent
report
clinic
featur
patient
also
found
higher
plasma
level
cytokin
intens
care
unit
icu
tocilizumab
recombin
human
monoclon
antibodi
act
receptor
antagonist
use
treatment
rheumatoid
one
studi
china
recruit
patient
sever
critic
patient
lower
need
oxygen
supplement
receiv
tocilizumab
mg
iv
infus
three
patient
anoth
dose
administ
due
continu
fever
within
hour
nineteen
patient
discharg
averag
day
hospit
time
treatment
us
food
drug
administr
fda
also
approv
phase
iii
clinic
trial
evalu
tocilizumab
hospit
patient
sever
pneumonia
meanwhil
sarilumab
anoth
receptor
antagonist
also
launch
phase
iiiii
clinic
trial
evalu
efficaci
patient
sever
infect
spread
continu
rapid
pace
confirm
case
exceed
march
measur
stop
pandem
discov
identifi
effect
treatment
prophylact
agent
crucial
date
sever
agent
demonstr
efficaci
human
mostli
case
report
preliminari
data
clinic
trial
small
sampl
size
mani
ongo
random
control
trial
current
conduct
confirm
result
joint
effort
healthcar
profession
scientif
commun
worldwid
new
evid
manag
expect
reveal
shortli
although
potenti
treatment
agent
discuss
may
provid
clinic
benefit
also
note
medic
may
lead
substanti
side
effect
healthcar
profession
take
great
caution
practic
